2 Minute Medicine: Pharma Roundup – Gastric Immunotherapy Gains, Prostate Pill Expansion, Five-Minute Myeloma Dosing, and Streamlined CAR-T Access [July 8th 2025]

Imfinzi Combo Cuts Gastric Cancer Risk by Twenty Nine Percent
Earlier this week at the American Society of Clinical Oncology meeting, investigators presented results from the nine hundred fifty patient MATTERHORN study showing that peri operative durvalumab plus FLOT reduced the combined risk of progression, recurrence, or death by twenty nine percent. Researchers used a nimble liquid biopsy strategy to monitor minimal residual disease in real time, eliminating the need for extra scans. A peer reviewed analysis in the New England Journal of Medicine confirmed that adverse events remained manageable, reinforcing enthusiasm for immunotherapy before and after surgery. Scientists at AstraZeneca signaled rapid global filings and argued that the data justify fast track consideration. Memorial Sloan Kettering’s Yelena Janjigian told Reuters the result is practice changing for roughly forty thousand resectable cases seen each year across the G-7. Editorial writers at The ASCO Post called MATTERHORN the most important peri operative gastric study in a decade. Surgeons now debate how best to integrate liquid biopsy monitoring into routine care. Turning from the stomach to the prostate, the next story explores a newly broadened oral therapy.

Nubeqa Moves to Front Line Prostate Care
On June 3, the US Food and Drug Administration removed chemotherapy prerequisites and cleared darolutamide for all men with metastatic castration sensitive prostate cancer receiving hormone suppression. The phase three ARANOTE trial showed that darolutamide plus androgen deprivation cut radiographic progression by forty six percent and delayed quality of life decline, findings highlighted by OncLive. A bedside review in Medscape emphasized a seizure risk below one percent, a reassuring detail for frail patients. Bloomberg reported that Bayer still targets three billion euro peak sales, confident the clean profile will help the pill overtake Xtandi in first line practice. Insurers are already updating pathways, and payers expect nationwide formulary adoption by early July. Veterans’ hospitals, where many patients cannot tolerate docetaxel, anticipate immediate switches to oral therapy. As oncologists absorb these changes, the spotlight shifts to multiple myeloma, where a wearable injector promises to save hours in the infusion chair.

Five Minute Sarclisa Dosing via Wearable Injector
Yesterday at ASCO, investigators announced that subcutaneous Sarclisa delivered with the hands free enFuse device matched intravenous efficacy while shrinking chair time from three hours to about five minutes. The phase three IRAKLIA study reported near identical overall response rates and no unexpected safety signals, paving the way for regulatory submissions in the first half of twenty twenty five. A pharmacokinetic analysis released through GlobeNewswire confirmed bioequivalence between delivery routes. Analysts interviewed by Pharmaphorum said the convenience could help Sarclisa close the sales gap with Darzalex, which already offers a rapid push formulation. The enFuse system from Enable Injections allows nurses to initiate dosing then step away, freeing slots for complex cell therapies and reducing staffing pressure. Advocacy groups predict improved adherence and quality of life once at home administration becomes feasible. Clinics are now retooling workflows to accommodate wearable injections. Our final story stays with cellular therapy, highlighting an FDA move that could widen access across community centers.

FDA Lifts REMS Barriers for Community CAR T Treatment
Earlier this week, the FDA eliminated Nationwide Risk Evaluation and Mitigation Strategy requirements for BCMA and CD19 directed CAR T therapies, a change that removes duplicate certification steps for hospitals and outpatient clinics. The agency said accumulating real world evidence supports streamlined monitoring, a stance applauded in The Wall Street Journal’s coverage. Oncologists interviewed by Health Affairs predicted the policy will accelerate uptake in community settings where advanced cell therapy was previously unavailable. Patient advocates remind clinicians that delayed cytokine release syndrome can still occur, urging robust follow up. Academic centers welcome the change because it may reduce referral bottlenecks and shorten wait lists, which in some regions stretch beyond two months. Analysts at the National Cancer Institute estimate that more than five hundred additional sites could now qualify to administer CAR T treatment. Manufacturers say broader distribution will cut travel burdens that often approach two hundred miles for rural patients. Health systems are drafting new protocols to train staff and secure reimbursement before year end.